ASH 2020

Convalescent plasma therapy may “potentiate the increased thrombotic risk and endotheliopathy” thought to contribute to disease pathophysiology in COVID-19.

CAR-T therapy demonstrated promising antitumor activity with low rates of grade 3 or higher CRS and neurotoxicity among patients with MCL.

CAR-T therapy induced high CR rates among patients with indolent NHL subtypes, including follicular lymphoma and marginal cell lymphoma.

A multicenter, retrospective study demonstrated higher PFS and OS rates with allogeneic transplant for relapsed/refractory TCL.

The purpose of this study was to evaluate azacitidine in combination with CHOP in a PTCL population enriched for AITL.

The addition of romidepsin to CHOP did not improve PFS over CHOP alone among patients with previously untreated PTCL.

Now that the phase 2 dose is established, a randomization cohort will test the efficacy of the treatments in the LACEWING trial.

Census tract affluence, disadvantage, and segregation were all significant predictors of leukemia-related death.

The addition of daratumumab to pomalidomide and dexamethasone improved PFS among patients with relapsed-refractory MM.

Allogeneic T cells with off-the-shelf potential showed preclinical activity against SARS-CoV-2 and are now being evaluated in a clinical trial.